Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer

Basit Öğe Kaydı
dc.authoridSaim Furkan Sarıcı / 0000-0001-9662-3760
dc.authorscopusidSaim Furkan Sarıcı / 39962527400
dc.authorwosidSaim Furkan Sarıcı / FUI-0962-2022
dc.contributor.authorSarıcı, Saim Furkan
dc.contributor.authorAltundağ, Kadri
dc.date.accessioned2021-01-12T10:11:24Z
dc.date.available2021-01-12T10:11:24Z
dc.date.issued2020en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionScopus Yılı: 2021
dc.description.abstractPurpose: Eribulin mesylate is a non-taxane microtubule inhibitor which is a synthetic holichondrin B analog that can be used after anthracycline and taxane treatment in patients with metastatic breast cancer. We aimed to analyze the results of eribulin-trastuzumab combination in aggressively pretreated metastatic HER2-positive breast cancer patients. Methods: In this single-center study, the records of 36 patients with HER-2-positive metastatic breast cancer who received at least one cycle of eribulin-trastuzumab in our clinic between 2015 and 2018 were analyzed retrospectively. Kaplan-Meier survival analysis was used for progression-free survival (PFS), and overall survival (OS) analyzes. Two-sided p values <0.05 were considered statistically significant. Results: A total of 36 patients with metastatic breast cancer were eligible and included in this study. The median age of the patients was 41 years (range 20-60). Most patients were heavily pretreated with a median of 5 (range 3-8) previous chemotherapy lines before eribulin. At the end of the follow up period (February 2018) all patients received a median of 5.5 cycles of eribulin-trastuzumab. Partial response (PR) was achieved in 9 patients (25%) and stable disease (SD) in 17 patients (47%). Median PFS was 4 months (95% CI: 3.8-6.1), and median OS was 10 months (95% CI: 7.5-12.4). The most common adverse events were grade 1-2 anemia (n=12, 33%), neutropenia (n=12, 33%) and grade 3-4 neuropathy (n=4, 11.1%). Conclusion: Eribulin-trastuzumab combination is an effective and safe treatment option with a low toxicity profile for aggressively pre-treated patients with metastatic breast cancer.en_US
dc.identifier.endpage2569en_US
dc.identifier.issn1107-0625en_US
dc.identifier.issue6en_US
dc.identifier.pmid33455097en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2562en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1313
dc.identifier.volume25en_US
dc.identifier.wosWOS:000612011800005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorSarıcı, Saim Furkan
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEfficacyen_US
dc.subjectEribulinen_US
dc.subjectHER2-positiveen_US
dc.subjectMetastatic Breast Canceren_US
dc.subjectSurvivalen_US
dc.subjectTrastuzumaben_US
dc.titleEfficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast canceren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
25-6-2562.pdf
Boyut:
870.34 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu